Research and Markets: World Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Pipeline Review, H2 2015 - 43 Companies & 40 Drug Profiles

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/qsvsgv/plaque_psoriasis) has announced the addition of the "Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with the latest updates, and featured news and press releases.

It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and special features on late-stage and discontinued projects.

The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • 3SBio Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Avesthagen Limited
  • Avexxin AS
  • BIOCAD
  • Biocon Limited
  • Bionovis S.A.
  • Can-Fite BioPharma Ltd.
  • Celgene Corporation
  • Celltrion, Inc.
  • Creabilis S.A.
  • Delenex Therapeutics AG
  • Dermira Inc.
  • Epirus Biopharmaceuticals, Inc.
  • Forward Pharma A/S
  • Galectin Therapeutics, Inc.
  • Genor BioPharma Co., Ltd.
  • GlaxoSmithKline Plc
  • Hetero Drugs Limited
  • Idera Pharmaceuticals, Inc.
  • Invion Limited
  • Johnson & Johnson
  • Kadmon Corporation, LLC
  • Mabtech Limited
  • Maruho Co., Ltd.
  • Pfizer Inc.
  • Promius Pharma, LLC
  • Protalix BioTherapeutics, Inc.
  • Provectus Biopharmaceuticals, Inc.
  • R-Tech Ueno, Ltd.
  • TetraLogic Pharmaceuticals
  • Therapeutic Proteins International, LLC
  • UCB S.A.
  • Valeant Pharmaceuticals International, Inc.

Drug Profiles

  • (betamethasone dipropionate + calcipotriene)
  • (calcipotriene + betamethasone dipropionate)
  • (calcipotriene + betamethasone)
  • adalimumab biosimilar
  • AM-001
  • AVX-001
  • betamethasone valerate + maxacalcitol
  • bimekizumab
  • bleselumab
  • brodalumab
  • calcipotriene
  • CC-90005
  • CT-327
  • dalazatide
  • DFD-01
  • DFD-06
  • dimethyl fumarate
  • DLX-105
  • DNX-114
  • DNX-514
  • DRM-02
  • etanercept biosimilar
  • GK-664S
  • GRMD-02
  • GSK-2981278
  • guselkumab
  • IDP-118
  • IDP-122
  • IMO-8400
  • IMP-731
  • infliximab biobetter
  • INV-103
  • KD-025
  • LEO-32731
  • LP-0113

For more information visit http://www.researchandmarkets.com/research/qsvsgv/plaque_psoriasis.

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders